Q&A: Understanding the Kent meningitis B outbreak and the response

The ongoing meningitis outbreak in Kent has brought up many questions for nurses as well as the general public. Therefore, we reached out to senior research fellow, Dr Michael Head, at the University of Southampton to answer some pressing questions on the matter.

Q: What has caused the current meningitis outbreak and why is it so concerning?

The cause of the outbreak is meningitis B.

This is caused by the bacterium Neisseria meningitidis, which has a number of different serogroups. Meningococcal serogroup B is the cause of meningitis B. Other common serogroups include A, C, W and Y.

These bacteria live harmlessly in the nose and throat of around 5-10% of the UK population,¹ and spread between individuals typically occurs through coughing, sneezing, kissing or during close contact with a carrier. When the bacteria invade and cause disease, it is often serious with clinical presentation including inflammation within the brain and sepsis. This invasion happens by the bacteria crossing the mucosal lining at the nasopharynx (area at the back of the nose and throat) and entering the bloodstream.

The risk of this is highest after picking up a new strain of the bacteria and before immunity develops, which is more likely when mixing with new populations – such as when starting at university and participating in social events.¹

From there, they penetrate the blood-brain barrier to reach the brain and spinal cord. Deterioration in the patient can be extremely rapid.

In this Kent outbreak, as of 24 March 2026, there have been 20 confirmed cases and two probable cases – including two tragic deaths. All reported cases have been hospitalised to date.² Typically we may only see one isolated case, or perhaps two or three linked cases. This Kent outbreak is unusual with the case numbers and pace of the transmission. The UK Health Security Agency (UKHSA) have highlighted how most outbreaks typically involve 2-4 cases over a longer period of time, whereas here we have seen 15 cases within 48 hours.³

The meningococcal bacteria isolated from the cases is also a new subtype;⁴ this variation may allow the bacteria to have some form of evolutionary advantage, such as increased capability to invade and infect, and/or transmit more easily. The UKHSA’s investigation into this subtype is ongoing.

Q: Who is currently being offered prophylactic antibiotics and who is being offered the MenB vaccine as part of the outbreak response — what is the rationale for each intervention?

The NHS has set up an online information hub.⁵ As of 30 March, 13,524 doses of antibiotic had been distributed, along with 11,415 meningitis B vaccinations.

Antibiotics, specifically ciprofloxacin, and the Bexsero men B vaccine have been made available to potential contacts. Practitioners would need to refer to the definition of close contact here,⁶ which is those who have had prolonged, direct exposure to an infected person’s respiratory droplets or oral secretions within seven days of the symptoms presenting in the related case. This may include members of the same household as a case, intimate partners, or having been sharing food, vapes, or drinks.

Antibiotics and vaccines have been made available a little more widely outside of specifically close contacts. This includes some students and staff at the University of Kent, sixth form students from a nearby college, and attendees at Club Chemistry, the nightclub where the outbreak is thought to have begun.

Antibiotics are considered the primary prophylaxis strategy for tackling transmission, because they can be effective even if an individual is in the latent period of developing an infection. Evidence suggests that antibiotics are effective at reducing the risk of secondary cases in household contacts by around 89%.⁷

Q: If a patient presents to their GP practice or pharmacy having been identified as a close contact of a confirmed case, what are the practical containment steps and what prophylaxis advice should primary care providers be giving them?

The current NHS advice is that close contacts are likely to be eligible for the prophylactic antibiotics, and also a MenB vaccine.⁶ They should be informed of the key signs and symptoms of meningitis, and urged to phone 111 or 999 if they have any concerns. There is no new meningitis-specific guidance regarding the use of facemasks in relation to this outbreak. However, existing UKHSA advice recommends that individuals with symptoms of a respiratory infection should wear a facemask if they need to go out.

Q: What if someone requests the vaccine but isn’t classed as at risk? Should children who have missed their routine MenB vaccination be prioritised?

From UK government guidance,⁹ ‘If your child has missed any of their MenB vaccines, they can still have the MenB vaccine up to the age of 2.’ Beyond this, at time of writing, the only individuals eligible for a vaccine dose on the NHS, outside of the routine schedule, are the potential close contacts of a case.¹⁰

There have been reports of supply chain issues with 87% of pharmacies reporting ‘considerable rises in requests’ for MenB vaccines which may exceed the level of supply.¹¹

Q: What are the symptoms of meningitis B that primary care providers should be alert to, and at what point should a patient be referred to secondary care as an emergency?

Meningococcal disease management guidelines indicate that all suspected cases should be transferred to hospital as an emergency.¹² There is the option to provide intravenous or intramuscular ceftriaxone or benzylpenicillin prior to transfer to hospital.

Key symptoms are varied and can be quite non-specific, for example including fever, a stiff neck, dislike of bright lights, and nausea.¹³ There may sometimes be the stereotypical rash that disappears under pressure. This rash can also be a key sign of sepsis.

Q: What are the current NHS vaccination schedules for MenB across different age groups? When was the routine MenB vaccination introduced – who is covered by it?

The current MenB vaccine was introduced into the UK in 2015, and the schedule is three doses in young children, one at 8 weeks , one at 12 weeks, and one at 12 to 13 months.¹⁴ The duration of protection is thought to be for a few years, thus protecting babies and younger children.¹⁵ However, immunity does wane within a few years,¹⁶ and there is not currently a routine dose later, for example in teenage years. Given the 2015 introduction, this does mean we currently have a cohort of teenagers and young adults who would likely not have been offered the MenB vaccine previously.

The government has asked the Joint Committee on Vaccination and Immunisation (JCVI) to review the evidence base around recommendations for who should be eligible for the meningitis B vaccine. The JCVI does not just consider safety and vaccine effectiveness. They are asked by the government to also review cost-effectiveness,¹⁷ in part using a metric quality-adjusted life years, QALYs.

In 2025, the minutes of the JCVI Meningococcal Sub-Committee show how the charity Meningitis Now had written to ask for consideration of a booster MenB vaccination programme in adolescents from 2030.¹⁸ The conclusions in the minutes are that the Secretariat would draft a response in relation to the Meningitis Now correspondence. Any change in policy would be the responsibility of the UK government.

Q: How should the vaccine be administered as part of the outbreak response — including route, dosing intervals, and any co-administration considerations primary care providers should be aware of?

Two doses are being administered as part of the outbreak response.¹⁹ The second dose should be given four weeks after the first dose. There are no specific interactions known between meningitis B and other vaccinations. It’s therefore unlikely to be problematic if any individual has had other immunisations around the same time as meningitis B.²⁰

Q: What are the most commonly reported side-effects of the MenB vaccine, how should primary care providers counsel patients and parents about managing them, and are there any contraindications clinicians should be aware of?

From the UK Green Book,²¹ the Men B vaccine should not be given to those who have had either a confirmed anaphylactic reaction to a previous dose, or a confirmed anaphylactic reaction to any component or residue from the manufacturing process.

From an overall safety perspective,²² there are the common mild and self-limiting side effects from vaccination. These are seen in up to one in ten adolescents and include pain at the injection site or a headache.

Q: How effective is the MenB vaccine in clinical practice, and does the vaccine in current use provide protection against the specific strain driving this outbreak?

There is good effectiveness data from a variety of countries and settings.¹⁶ In the UK, the Bexsero vaccine was found to be 83% effective against all MenB disease in infants eligible for the vaccine. Further research observed a 75% reduction in MenB disease in eligible age groups, resulting in an estimated 277 cases prevented in the first three years of the programme.

It’s fair to assume that most these prevented cases would have needed hospitalisation, and with an approximate 10% mortality rate, then significant healthcare resource and around 27 deaths have been averted in this scenario.

In the Kent outbreak, a UKHSA technical briefing published on 24 March indicated that ‘The current data suggest the strain is both susceptible to common antibiotics and covered by the two MenB vaccines licensed in the UK’.²³

Dr Michael Head is a senior research fellow in global health who specialises in public health research and epidemiology at the University of Southampton.

A version of this article was first published on our sister title, The Pharmacist.

References

GOV.UK. Meningococcal carriage and infection: technical background. https://www.gov.uk/guidance/meningococcal-carriage-and-infection-technical-background.
GOV.UK. Notified cases of invasive meningococcal disease. https://www.gov.uk/government/publications/invasive-meningococcal-disease-statistical-releases/notified-cases-of-invasive-meningococcal-disease.
UK Health Security Agency. Meningitis outbreak: what you need to know. https://ukhsa.blog.gov.uk/2026/03/18/meningitis-b-outbreak-what-you-need-to-know/?utm.
The Pharmacist. Kent meningitis outbreak driven by a ‘recently emerged’’ disease subtype. https://www.thepharmacist.co.uk/clinical/vaccinations-and-infections/kent-meningitis-outbreak-driven-by-a-recently-emerged-disease-subtype/
Meningitis outbreak information hub. https://www.kmhealthandcare.uk/meningitis-information/.
Frequently asked questions. https://www.kmhealthandcare.uk/meningitis-faqs.
GOV.UK. Guidance for public health management of meningococcal disease in the UK. https://www.gov.uk/government/publications/meningococcal-disease-guidance-on-public-health-management.
Meningitis information for students. https://www.kmhealthandcare.uk/meningitis-information-for-students.
UK Health Security Agency. Who is eligible for the MenB vaccine and do I need it myself? https://ukhsa.blog.gov.uk/2026/03/20/who-is-eligible-for-the-menb-vaccine-and-do-i-need-it-myself/.
Antibiotic and vaccine clinics. https://www.kmhealthandcare.uk/meningitis-antibiotic-and-vaccine-clinics.
Pharmaceutical Journal. Wholesalers ‘working through’ increased demand for meningitis vaccination. https://pharmaceutical-journal.com/article/news/wholesalers-working-through-increased-demand-for-meningitis-vaccination.
GOV.UK. Guidance for public health management of meningococcal disease in the UK. https://www.gov.uk/government/publications/meningococcal-disease-guidance-on-public-health-management.
Meningitis Symptoms. 2026. https://www.nhs.uk/conditions/meningitis/symptoms/.
NHS Inform. Meningococcal B vaccine. https://www.nhsinform.scot/healthy-living/immunisation/meningococcal-b-menb-vaccine/.
Ladhani SN, Andrews N, Parikh SR, et al. Vaccination of Infants with Meningococcal Group B Vaccine (4CMenB) in England. New England Journal of Medicine 2020; 382: 309–17.
GOV.UK. Meningococcal B vaccination programme for infants: information for healthcare practitioners. https://www.gov.uk/government/publications/meningococcal-b-vaccine-information-for-healthcare-professionals/meningococcal-b-vaccination-programme-for-infants-information-for-healthcare-practitioners.
Should NICE’s cost-effectiveness thresholds change? https://www.nice.org.uk/news/blogs/should-nice-s-cost-effectiveness-thresholds-change-
Minutes of JCVI Meningococcal Sub-Committee. https://app.box.com/s/ov3lq8zsrg0th9fe3xf1u8i21u2cde2g/file/2044051813335.
UK Health Security Agency. Who is eligible for the MenB vaccine and do I need it myself? https://ukhsa.blog.gov.uk/2026/03/20/who-is-eligible-for-the-menb-vaccine-and-do-i-need-it-myself/.
The Australian Immunisation Handbook. Meningococcal disease. https://immunisationhandbook.health.gov.au/contents/vaccine-preventable-diseases/meningococcal-disease#contraindications-and-precautions.
UK Health Security Agency. Green Book chapter 22 – Meningococcal meningitis and septicaemia. https://assets.publishing.service.gov.uk/media/6849adb83a2aa5ba84d1df71/Meningococcal-green_book_chapter-22-10-6-25.pdf.
Vaccine Knowledge Project. MenB Vaccine. https://vaccineknowledge.ox.ac.uk/menb-vaccine#Safety-and-side-effects.
UK Health Security Agency. Invasive Meningococcal Disease outbreak 2026: technical briefing 1. https://www.gov.uk/government/publications/invasive-meningococcal-disease-outbreak-2026-technical-briefings/invasive-meningococcal-disease-outbreak-2026-technical-briefing-1.